Access to new cancer medicines in Australia: dispelling the myths and informing a public debate

Journal of Pharmaceutical Policy and Practice

Barbara Mintzes¹  Wendy Lipworth¹  Agnes Vitry¹ 

[1] Faculty of Pharmacy, Bias and Research Integrity Node, Charles Perkins Centre, University of Sydney, Johns Hopkins Drive, Camperdown, NSW 2050 Australia

关键词: Cancer medicines;    Funding;    High prices;    Consumer engagement;    Transparency;    Public debate;   

DOI  :  10.1186/s40545-016-0062-x

学科分类：药理学

来源: BioMed Central

【 摘 要 】

Despite the high level of spending on cancer medicines in Australia, consumer organisations and the pharmaceutical industry often make claims of delayed or lack of access to new cancer medicines—claims that are frequently supported by prominent coverage in the Australian media. These claims, while morally and psychologically compelling, tend to ignore the complexity of medicines funding decisions. In this commentary we summarise the current situation regarding the registration and funding of cancer medicines in Australia, elucidate the main challenges associated with access to cancer medicines in the Australian context, and describe some of the steps that have been taken to address these challenges.

【 授权许可】

Unknown